Pres, CEO
Dror Bashan is the President, Chief Executive Officer, and a director of Protalix BioTherapeutics, Inc. (NASDAQ: PLX), positions he has held since June 30, 2019.[[1]](https://fintool.com/app/research/companies/PLX/people/dror-bashan)[[3]](https://protalix.com/about) With over 20 years of experience in the pharmaceutical industry, he previously served in senior roles at Teva Pharmaceutical Industries from 1998 to 2018, including Senior Vice President of Global Business Development, where he led strategic alliances, M&A, and divestitures across business development, marketing, sales, and finance.[[1]](https://fintool.com/app/research/companies/PLX/people/dror-bashan)[[3]](https://protalix.com/about)
Bashan holds a BA in Economics & Business Management and an MBA from Tel Aviv University, and is 58 years old as of 2025.[[1]](https://fintool.com/app/research/companies/PLX/people/dror-bashan) Under his leadership, Protalix achieved FDA and EMA approvals for Elfabrio (pegunigalsidase alfa) in 2023, advanced PRX-115 into first-in-human trials, and saw total shareholder return rise significantly, alongside a shift to positive net income ($8.3M in 2023, $2.9M in 2024).[[1]](https://fintool.com/app/research/companies/PLX/people/dror-bashan) Recently, on December 19, 2025, he purchased 56,000 shares for $101,360, owning 188,516 shares directly and 2,344,418 indirectly through a trust, reflecting confidence in the company.[[2]](https://www.investing.com/news/insider-trading-news/bashan-dror-protalix-biotherapeutics-ceo-buys-101k-in-shares-93CH-4421002)[[5]](https://www.tradingview.com/news/tradingview:27e640881e548:0-protalix-biotherapeutics-ceo-dror-bashan-acquires-56-000-shares/)
View full insider profile →
